Korea Investment CORP Sells 16,600 Shares of Humana Inc. $HUM

Korea Investment CORP lessened its stake in shares of Humana Inc. (NYSE:HUM) by 22.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 56,816 shares of the insurance provider’s stock after selling 16,600 shares during the period. Korea Investment CORP’s holdings in Humana were worth $14,782,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of HUM. Munich Reinsurance Co Stock Corp in Munich acquired a new position in shares of Humana during the third quarter valued at about $5,395,000. First Trust Advisors LP grew its stake in shares of Humana by 131.4% in the 3rd quarter. First Trust Advisors LP now owns 126,585 shares of the insurance provider’s stock valued at $32,934,000 after buying an additional 71,875 shares during the period. HUB Investment Partners LLC increased its position in Humana by 42.2% in the 3rd quarter. HUB Investment Partners LLC now owns 1,234 shares of the insurance provider’s stock valued at $321,000 after buying an additional 366 shares in the last quarter. Neuberger Berman Group LLC increased its position in Humana by 2,855.5% in the 3rd quarter. Neuberger Berman Group LLC now owns 530,775 shares of the insurance provider’s stock valued at $138,092,000 after buying an additional 512,816 shares in the last quarter. Finally, Pitcairn Co. raised its stake in Humana by 29.2% during the 3rd quarter. Pitcairn Co. now owns 2,296 shares of the insurance provider’s stock worth $597,000 after buying an additional 519 shares during the period. 92.38% of the stock is owned by institutional investors.

Humana Stock Performance

Shares of HUM opened at $170.94 on Thursday. The firm has a market capitalization of $20.52 billion, a P/E ratio of 17.41, a P/E/G ratio of 1.78 and a beta of 0.44. Humana Inc. has a 52 week low of $169.61 and a 52 week high of $315.35. The stock has a 50 day moving average price of $216.73 and a two-hundred day moving average price of $249.74. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter last year, the company earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, March 27th. This represents a $3.54 annualized dividend and a yield of 2.1%. Humana’s dividend payout ratio (DPR) is 36.05%.

Insider Transactions at Humana

In other news, insider Sanjay K. Shetty bought 810 shares of Humana stock in a transaction dated Monday, February 23rd. The stock was purchased at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the purchase, the insider directly owned 11,657 shares in the company, valued at $2,158,992.97. The trade was a 7.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.37% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Raymond James Financial reduced their price objective on Humana from $340.00 to $230.00 and set an “outperform” rating for the company in a research note on Friday, February 13th. Leerink Partners lowered their target price on Humana from $267.00 to $185.00 and set a “market perform” rating on the stock in a research report on Thursday, February 12th. Oppenheimer set a $250.00 target price on Humana in a report on Thursday, February 12th. Wolfe Research lifted their price target on shares of Humana from $300.00 to $325.00 and gave the company an “outperform” rating in a research report on Thursday, January 8th. Finally, TD Cowen decreased their price target on shares of Humana from $260.00 to $173.00 and set a “hold” rating for the company in a research note on Friday, February 13th. Seven investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus target price of $225.48.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.